Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer.
Yiqiao Fang, Cheng Yi, Ruonan Sun et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined recurrence in head and neck cancer (HNC), combining 1060 studies of 336,615 patients and 1.40 million person-years of follow-up. Person-time analysis estimated a global recurrence rate of 6.57 per 100 person-years (95% CI, 6.28-6.87). Rates were higher in lower-middle-income countries and hypopharyngeal cancers. The prognostic effects of age and tumor stage were strongest early after treatment and diminished over time. Among patients with recurrent disease, the pooled case fatality rate was 55.80% (95% CI, 51.20-60.30).
Key findings
- The global HNC recurrence rate was 6.57 per 100 person-years (95% CI, 6.28-6.87).
- Rates were 10.16 per 100 person-years in lower-middle-income countries and 14.11 per 100 person-years in hypopharyngeal cancers.
- Median follow-up duration explained 37.12% of between-study heterogeneity; shorter reported follow-up tended to accompany higher annualized rates.
- Pooled case fatality among patients with recurrent disease was 55.80% (95% CI, 51.20-60.30).
Why it matters
The findings quantify recurrence burden across a large, diverse evidence base and show that risk varies by setting, cancer site, and time after treatment. The high pooled case fatality underscores the clinical importance of recurrence. Time-dependent prognostic patterns may help inform how surveillance and prevention strategies are considered, while differences in follow-up complicate comparisons between studies.
What to keep in mind
The review found substantial between-study heterogeneity, and median follow-up duration was an important contributor; annualized rates may therefore be difficult to compare across studies with different follow-up.